Research

Hormonal

There is no head-to-head evidence to determine which drug class (THR-β vs Incretins) is superior for histological outcomes in MASH.

Both resmetirom and incretins work for MASH, but we don't know which is better for the liver itself because no study has compared them directly.

StrongQualifiesVERY_HIGH confidence
no head-to-head comparisons exist... The results showed that all active therapies outperformed placebo on at least one biopsy-anchored endpoint.
Amirah A Alzaki et al. · Cureus · 2026

Why this rating

Based on the absence of direct trials.

Source

THR-β Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty

Amirah A Alzaki et al. · Cureus · 2026

DOI 10.7759/cureus.106038

systematic_review · n=3796
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →